Vor BioPharma Inc (VOR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$25.05+3.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Vor BioPharma has about $450 million in cash as of 2025-Q4. The company raised $225 million in private placements in the last two quarters. This funding supports its cell therapy development through mid-2028. The stable market and no recent negative news add to confidence.
Vor BioPharma is loss-making with negative EPS expected through 2027. The company depends heavily on raising capital to fund operations. Management changes and volatile execution raise risks. If funding or clinical progress falters, the stock could suffer.
There is no clear market consensus or price target available. The lack of analyst revenue estimates and negative EPS forecasts suggest the market prices in ongoing losses and funding needs. Our view is cautious given the speculative nature of the turnaround.
Breaks if: failure to raise at least $75 million in any quarter if cash runway threatened
Breaks if: cash falls below $300 million before mid-2028
Breaks if: quarterly operating loss exceeds $50 million persistently
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is in the early stages of developing its product, telitacicept, but faces significant challenges in execution and financial stability.
The market appears to be pricing in a low level of execution quality and a turbulent sector backdrop. However, there is a fragility in the current setup, as the stock does not reflect the full extent of its weak performance and high-risk profile.
Fundamentals are likely to remain weak in the near term, as the company continues to report operating losses. Management is focused on advancing product development and securing regulatory approvals, but these efforts have not yet translated into financial success.
The future of VOR hinges on several factors, including the company's ability to maintain its capital runway and the performance of sector bellwethers. Additionally, any changes in guidance or economic conditions that affect the healthcare sector could significantly impact VOR.
In the next 1 to 3 years, VOR's outlook is uncertain due to its high-risk profile and recent performance decline. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance fell from the top half to the bottom half of its industry. This change indicates that the reason to own VOR has weakened. The market has not yet reacted to these weaker fundamentals, as the price is up 12% versus the S&P since then.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.